Latest period
$353.10M
YoY change
+1.3%
5Y CAGR
+12.8%
Peak year (2021)
$389.20M
Cumulative CapEx
$2.46B
CapEx history chart for DexCom (DXCM) from 2003 to 2025
Latest: $363.50M
CapEx growth chart for DexCom (DXCM) from 2003 to 2025
Latest: +1.3%
CapEx history table for DexCom (DXCM) from 2003 to 2025
| 2025 | $363.50M | +1.3% | +$4.70M | ||
| 2024 | $358.80M | +51.6% | +$122.20M | ||
| 2023 | $236.60M | -35.1% | −$128.20M | ||
| 2022 | $364.80M | -6.3% | −$24.40M | ||
| 2021 | $389.20M | +95.6% | +$190.20M | ||
| 2020 | $199.00M | +10.6% | +$19.00M | ||
| 2019 | $180.00M | +168.3% | +$112.90M | ||
| 2018 | $67.10M | +1.7% | +$1.10M | ||
| 2017 | $66.00M | +18.5% | +$10.30M | ||
| 2016 | $55.70M | +67.3% | +$22.40M | ||
| 2015 | $33.30M | +105.6% | +$17.10M | ||
| 2014 | $16.20M | +105.1% | +$8.30M | ||
| 2013 | $7.90M | -16.8% | −$1.60M | ||
| 2012 | $9.50M | +18.7% | +$1.49M | ||
| 2011 | $8.01M | +16.7% | +$1.15M | ||
| 2010 | $6.86M | +129.3% | +$3.87M | ||
| 2009 | $2.99M | +20.1% | +$500.00K | ||
| 2008 | $2.49M | -27.6% | −$951.00K | ||
| 2007 | $3.44M | +2.7% | +$90.89K | ||
| 2006 | $3.35M | -28.3% | −$1.32M | ||
| 2005 | $4.68M | +166.1% | +$2.92M | ||
| 2004 | $1.76M | +330.1% | +$1.35M | ||
| 2003 | $408.61K | — | — |
- 2025$363.50M+1.3%
- 2024$358.80M+51.6%
- 2023$236.60M-35.1%
- 2022$364.80M-6.3%
- 2021$389.20M+95.6%
- 2020$199.00M+10.6%
- 2019$180.00M+168.3%
- 2018$67.10M+1.7%
- 2017$66.00M+18.5%
- 2016$55.70M+67.3%
- 2015$33.30M+105.6%
- 2014$16.20M+105.1%
- 2013$7.90M-16.8%
- 2012$9.50M+18.7%
- 2011$8.01M+16.7%
- 2010$6.86M+129.3%
- 2009$2.99M+20.1%
- 2008$2.49M-27.6%
- 2007$3.44M+2.7%
- 2006$3.35M-28.3%
- 2005$4.68M+166.1%
- 2004$1.76M+330.1%
- 2003$408.61K—
CapEx values are taken from DexCom's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at DexCom (DXCM)
According to DexCom's latest reported financial statements, the company's current CapEx (TTM) is $353.10M. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, DexCom (DXCM) CapEx totalled $363.50M – edged up 1.3% year-over-year.
DexCom CapEx compound annual growth for the 2020–2025 (5 years) window is +12.8%, sustaining 2 straight years of year-over-year growth.
DexCom CapEx peaked at $389.20M in 2021; the latest annual figure is $363.50M in 2025 (6.6% below peak).
$389.20M stands as the all-time-high annual CapEx, posted in 2021, against a low of $408.61K during 2003.
DexCom Capital Expenditures by Year
DexCom Capital Expenditures 2025: $363.50M
DexCom CapEx in 2025 was $363.50M, edged up 1.3% from 2024.
DexCom Capital Expenditures 2024: $358.80M
2024's CapEx for DexCom came in at $358.80M, surged 51.6% from 2023.
DexCom Capital Expenditures 2023: $236.60M
DexCom posted CapEx of $236.60M in 2023, plunged 35.1% below 2022.
DexCom Capital Expenditures 2022: $364.80M
In 2022, DexCom reported CapEx of $364.80M, declined 6.3% below 2021.
DexCom Capital Expenditures 2021: $389.20M
DexCom CapEx in 2021 was $389.20M.
See more financial history for DexCom (DXCM).
Sector peers by CapEx
Healthcare peers of DexCom (DXCM), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
DexCom (DXCM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation